Jonathan Siegal Sells 3,908 Shares of Vericel Co. (NASDAQ:VCEL) Stock

Vericel Co. (NASDAQ:VCEL) insider Jonathan Siegal sold 3,908 shares of the business’s stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $61.99, for a total transaction of $242,256.92. Following the completion of the sale, the insider now owns 1,206 shares in the company, valued at $74,759.94. This represents a 76.42 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Vericel Stock Performance

NASDAQ VCEL opened at $59.25 on Friday. Vericel Co. has a 52 week low of $39.12 and a 52 week high of $61.99. The stock has a market capitalization of $2.92 billion, a P/E ratio of 987.66 and a beta of 1.72. The stock has a fifty day moving average of $57.66 and a 200-day moving average of $50.75.

Vericel (NASDAQ:VCEL) last announced its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.02) EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.03. Vericel had a return on equity of 1.48% and a net margin of 1.56%. The firm had revenue of $57.91 million during the quarter, compared to analyst estimates of $55.32 million. Equities research analysts forecast that Vericel Co. will post 0.12 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Canaccord Genuity Group restated a “buy” rating and issued a $60.00 price target on shares of Vericel in a research report on Tuesday, November 19th. BTIG Research boosted their target price on Vericel from $56.00 to $66.00 and gave the stock a “buy” rating in a report on Tuesday, November 26th. Stephens reaffirmed an “overweight” rating and set a $65.00 price target on shares of Vericel in a report on Wednesday, January 15th. HC Wainwright reiterated a “buy” rating and issued a $60.00 price objective on shares of Vericel in a research report on Wednesday, January 15th. Finally, Truist Financial increased their target price on Vericel from $61.00 to $67.00 and gave the stock a “buy” rating in a report on Wednesday, December 18th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $62.14.

Hedge Funds Weigh In On Vericel

Large investors have recently bought and sold shares of the business. Geneva Capital Management LLC lifted its stake in shares of Vericel by 61.4% in the 3rd quarter. Geneva Capital Management LLC now owns 1,104,386 shares of the biotechnology company’s stock valued at $46,660,000 after purchasing an additional 420,078 shares during the period. Wellington Management Group LLP increased its holdings in Vericel by 214.0% in the third quarter. Wellington Management Group LLP now owns 587,857 shares of the biotechnology company’s stock valued at $24,837,000 after purchasing an additional 400,667 shares during the last quarter. Congress Asset Management Co. lifted its stake in Vericel by 37.4% in the third quarter. Congress Asset Management Co. now owns 1,291,720 shares of the biotechnology company’s stock valued at $54,575,000 after buying an additional 351,550 shares during the period. TimesSquare Capital Management LLC boosted its holdings in Vericel by 54.8% during the third quarter. TimesSquare Capital Management LLC now owns 590,145 shares of the biotechnology company’s stock worth $24,934,000 after buying an additional 209,009 shares during the last quarter. Finally, Polar Asset Management Partners Inc. acquired a new position in shares of Vericel during the 3rd quarter worth about $4,973,000.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.